Trial Profile
Efficacy and Safety of Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis with and Without Fever
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2015
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- 22 Jul 2015 New trial record
- 13 Jun 2015 Interim results in 122 patients presented at the 16th Annual Congress of the European League Against Rheumatism.